Epic Sciences Inc News Today

/PRNewswire/ -- The "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path...

Dublin, May 10, 2023 (GLOBE NEWSWIRE) -- The "Next Generation Cancer Diagnostics: Technologies and Global Markets" report has been added to ...

/PRNewswire/ -- The "Next Generation Cancer Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.coms offering. The base...

The 56-gene ctDNA panel is a key component of DefineMBC™, the company’s comprehensive blood biopsy for metastatic breast cancerSAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (admi...

Funding will accelerate commercial launch of DefineMBC™SAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months. T...

/PRNewswire/ -- The "Liquid Biopsy Market Research Report: Forecast (2023-2028)" report has been added to ResearchAndMarkets.coms offering. The analyst just...

/PRNewswire/ -- The "Global Microarray Market Trends and Forecasts" report has been added to ResearchAndMarkets.coms offering. This report incorporates an...

/PRNewswire/ -- The "Global Microarray Market Trends and Forecasts" report has been added to ResearchAndMarkets.coms offering. This report incorporates an...

Global Liquid Biopsy Market Size, Historical Analysis, and Industry Growth Factors for Research Data from 2021 to 26

High Prevalence of Cancer Curating the Fundamentals Underlying the Dynamics of Liquid Biopsy Market